Axcan & Eurand change to Aptalis
Axcan Intermediate Holdings has changed its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies focused on gastrointestinal diseases: Axcan and Eurand.
Aptalis currently markets several products around the world and has several compounds in various stages of development targeting unmet medical needs. The pipeline includes a recent acquisition, Aeroquin from Mpex Pharmaceuticals, currently in phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.